Name: LML4801 Assignment 2 Semester 1 Memo | Due 25 April 2025 - StudyPass
Price: 100.00 ZAR
Availability: InStock

LML4801 Assignment 2 Semester 1 Memo | Due 25 April 2025

R100.00
0 Downloads

LML4801 Assignment 2 Semester 1 Memo | Due 25 April 2025. All questions fully answered. Scenario Peter works for Pharmabayu Inc in South Africa, as a researcher testing various dosage regimes of known and new pharmaceutical compounds. While on holiday, he devises a new dosage regime for an existing pharmaceutical compound known to be used in cardiac arrythmia management medicine since 2004. Pharmabayu applies for a patent for which the patent claim for the patent (granted on 5 August 2023) reads as follows: ‘The use of the compound (maxorevo) for the manufacture of a medicament in an oral dosage form for the treatment of cardiac disorders for administration no more than once daily for at least seven consecutive days, where said compound has a plasma concentration half-life of 12 hours or less when orally administered to a human patient, wherein the cardiac disorder is arrhythmia, and wherein the oral dosage form is a rapid-release tablet.’ A rival pharmaceutical firm, R.D. Gen, decides to apply for the revocation of this patent to bring their own cardiac arrythmia medicine (which also makes use of maxorevo) to market. The maxorevo compound was first identified in March 2001.  Question 1 1. Outline the potentially viable revocation grounds that R.D. Gen might rely on for this application and comment on the likelihood of success for each ground.

Description

LML4801 Assignment 2 Semester 1 Memo | Due 25 April 2025. All questions fully answered. Scenario Peter works for Pharmabayu Inc in South Africa, as a researcher testing various dosage regimes of known and new pharmaceutical compounds. While on holiday, he devises a new dosage regime for an existing pharmaceutical compound known to be used in cardiac arrythmia management medicine since 2004. Pharmabayu applies for a patent for which the patent claim for the patent (granted on 5 August 2023) reads as follows: ‘The use of the compound (maxorevo) for the manufacture of a medicament in an oral dosage form for the treatment of cardiac disorders for administration no more than once daily for at least seven consecutive days, where said compound has a plasma concentration half-life of 12 hours or less when orally administered to a human patient, wherein the cardiac disorder is arrhythmia, and wherein the oral dosage form is a rapid-release tablet.’ A rival pharmaceutical firm, R.D. Gen, decides to apply for the revocation of this patent to bring their own cardiac arrythmia medicine (which also makes use of maxorevo) to market. The maxorevo compound was first identified in March 2001.  Question 1 1. Outline the potentially viable revocation grounds that R.D. Gen might rely on for this application and comment on the likelihood of success for each ground.